ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

ASN / Education & Meetings / Kidney Week /

Please note that you are viewing an archived section from 2019 and some content may be unavailable. To unlock all content for 2019, please visit the archives.

Abstract: FR-PO258

Temporal Trends in Pharmacologic Management of Diabetes Mellitus Among Patients with CKD in the United States

Session Information

Category: Diabetic Kidney Disease

  • 602 Diabetic Kidney Disease: Clinical

Authors

  • Murphy, Daniel P., University of Minnesota, Minneapolis, Minnesota, United States
  • Foley, Robert N., University of Minnesota, Minneapolis, Minnesota, United States
Background

The nexus of diabetes mellitus and chronic kidney disease (DM-CKD) constitutes a major public health problem. Though substantial therapeutic advances have occurred in the last decade, diabetes management patterns in the US DM-CKD population remain poorly delineated. Hence, we examined trends in anti-diabetic medication use among adult National Health and Nutrition Examination Survey participants from years 2001 to 2016.

Methods

Eligible participants had self-reported diabetes or HbA1c ≥ 7.0 % and creatinine-based estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73m2 or urinary albumin to creatinine ratio (ACR) ≥ 30 mg/g.

Results

Increases were observed in the proportions taking at least 1 anti-diabetic medication (1+ADM, 73.1% in 2001-2004, 79.2% in 2005-2008, 81.8% in 2009-2012 and 81.9% in 2013-2016, P=0.024). A biphasic pattern was observed for 2+ADM (33.6%, 43.7%, 42.0%, 31.9%, P=0.002). Regarding individual classes of ADM, values rose for biguanides (32.8%, 40.0%, 39.5%, 45%, P=0.048), insulin (26.9%, 27.8%, 38.7%, 39.4%, P=0.001) and meglitinides (0%, 3.5 %, 8.8%, 9.1%, P < 0.001); fell for sulphonylureas (35.9%, 38.3%, 37.1%, 23.6%, P < 0.001) and thiazolidinediones (19.2%, 21.1%, 9.8%, 3.6%, P < 0.001); exhibited a rise-and-fall pattern for alpha-glucosidase inhibitors (0.2%, 1.9%, 0.7% and 0.1%, P=0.015) and amylin analogs (0%, 1.9%, 0%, 0%, P=0.005) and remained statistically unchanged for dipeptidyl peptidase-4 inhibitors (6.5%, 6.5%, 4.5%, 3.7%, P=0.333) and SGLT-2 inhibitors 0%, 0.9%, 1.2% and 2.4%, P=0.091).

Conclusion

Thus, anti-diabetic medication use in the US DM-CKD populations has changed considerably between 2001 and 2016.